discontinuing treatment and predicting relapse in cml
Published 6 years ago • 1.3K plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
6:35
measuring residual disease in granulocytes to predict relapse after therapy cessation in cml
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
3:18
granulocytes & t-cells as biomarkers for relapse in cml following discontinuation of tkis
-
2:18
recommendations for treatment discontinuation in cml
-
2:46
optimizing preceding and consolidation therapies to prevent post-car-t relapse in b-all
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
2:34
improving outcomes for patients who relapse after allosct & evaluating cd19 cars against emd in all
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
37:22
eha 2024 recap: optimizing the relapsed/refractory cll treatment pathway
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:13
second-line treatment strategies for patients with relapsed dlbcl
-
3:27
therapeutic options for patients with primary refractory/early relapsed dlbcl
-
2:03
relapse incidence post-allosct with ptcy for aml in cr1
-
2:29
evaluating the combination of nivolumab and lenalidomide in relapsed hl and lbcl
-
2:22
the treatment of relapsed/refractory chronic lymphocytic leukemia
-
4:49
novel transplant strategies in aml and the importance of reducing the risk of relapse in patients
-
1:18
the epidemiology and treatment of chronic gvhd post-allosct
-
1:55
long-term monitoring, adherence & endpoints in cml